Completed PHASE3 INTERVENTIONAL 2-arm NCT01733459

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS)

Sponsor: Dexa Medica Group

Conditions Polycystic Ovary Syndrome (PCOS)

Interventions DLBS3233 Metformin XR Placebo caplet of Metformin XR Placebo capsule of DLBS3233

Updated 6 times since 2017 Last updated: Jul 24, 2018 Started: Mar 31, 2013 Primary completion: Apr 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01733459, this PHASE3 trial focuses on Polycystic Ovary Syndrome (PCOS) and remains completed. Sponsored by Dexa Medica Group, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dexa Medica Group

Data source: Dexa Medica Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandung, Indonesia
• Jakarta, Indonesia